Search
for
Sort by
Research 91–120 of 305
- α1A-blockers's combined with prozac for the treatment of premature ejaculation
- Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
- MP-09.08
- Medikamentöse Therapie des benignen Prostatasyndroms (BPS)
- Cost-minimization Analysis of 2 Drug Therapy Projects Including Traditional Chinese Medcines and Chemical Medcines in BPH Patients
- TACRINE
- Analysis of Cost-effectiveness of 4 Kinds of Projects for Drug Therapy in the Treatment of BPH
- UP-02.011 Biofeedback Treatment for Dysfunctional Voiding Diagnosed in Adulthood
- PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
- How to Read a Research Paper
- Factors predisposing to intraoperative floppy-iris syndrome: An up-to-date meta-analysis
- Medications Mostly Associated With Ejaculatory Disorders: Assessment of the Eudra-Vigilance and Food and Drug Administration Pharmacovigilance Databases Entries
- Analytical methods of dutasteride: An overview
- Floppy Iris Syndrome
- Intraoperative floppy iris syndrome
- Intraoperative Floppy Iris Syndrome: Updated Perspectives
- Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern Grundlagen und klinische Ergebnisse
- Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
- The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
- Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement
- Editorial Comment
- Clinical Pearls in Men's Health
- Editorial Comment
- Dutasteride
- BPH: costs and treatment outcomes.
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Review: Adding α<sub>1</sub>-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
- Risk factors for intraoperative floppy iris syndrome: One year prospective study
- Effects of <i>In Utero</i> Exposure to D-004, a Lipid Extract from <i>Roystonea regia</i> Fruits, in the Male Rat: A Comparison with Finasteride